Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DRALZINE vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dralzine is a direct-acting arteriolar vasodilator that relaxes vascular smooth muscle, leading to decreased systemic vascular resistance and afterload. The exact molecular mechanism is not fully elucidated but involves inhibition of calcium influx and interference with the contractile process.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Essential hypertension (off-label),Hypertensive crisis (off-label)
Hypertension
Oral: 50-100 mg twice daily; maximum 200 mg/day.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Terminal elimination half-life is 2-5 hours in patients with normal renal function; prolonged to 10-20 hours in renal impairment.
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Primarily hepatic via N-acetyltransferase (NAT2); exhibits polymorphic acetylation. Metabolites include hydralazine pyruvate hydrazone and other hydrazone derivatives.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Primarily renal (70-90% as unchanged drug and metabolites); biliary/fecal excretion accounts for <10%.
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
85-90%, primarily to albumin.
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
1.5-2.0 L/kg; indicates extensive tissue distribution, exceeding total body water.
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral: 30-50% due to first-pass metabolism.
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
GFR 10-50 m L/min: 50 mg twice daily; GFR <10 m L/min: 50 mg once daily.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: 50 mg twice daily; Child-Pugh C: avoid use.
Child-Pugh Class B or C: contraindicated; use not recommended.
1-2 mg/kg/day divided every 12 hours; maximum 5 mg/kg/day.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Initiate at 25 mg twice daily; titrate slowly to avoid hypotension.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
None.
None
May induce a lupus-like syndrome, especially in slow acetylators; monitor for symptoms such as arthralgia, fever, and rash.,May cause drug-induced autoimmune hepatitis.,Can precipitate angina or myocardial infarction in patients with coronary artery disease.,Risk of hypotension and reflex tachycardia.
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Hypersensitivity to hydralazine or components,Coronary artery disease (relative contraindication due to risk of myocardial ischemia),Mitral valve rheumatic heart disease (relative),Idiopathic lupus erythematosus
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
DRALZINE should be taken with or without food, but consistent timing is recommended. High-tyramine foods (e.g., aged cheeses, cured meats, fermented products) may increase the risk of hypertensive crisis in patients also taking MAOIs; however, interactions with food are otherwise minimal. Avoid large, high-fat meals as they may affect absorption.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
First trimester: No evidence of teratogenicity in human studies; however, consider fetal hypotension and impaired uteroplacental perfusion. Second and third trimesters: Risk of fetal hypotension, adverse fetal heart rate patterns, and neonatal adverse effects (hypotension, tachycardia, fluid retention).
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Compatible with breastfeeding. M/P ratio not established; drug appears in breast milk in low amounts (<1% maternal dose). No reported adverse effects in infants.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
No specific dose adjustments required based on pharmacokinetic changes in pregnancy. However, because of increased blood volume, higher doses may be needed to achieve same antihypertensive effect; titrate to target blood pressure.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
DRALZINE (hydralazine) is a direct-acting vasodilator used primarily for hypertension, especially in pregnancy (pre-eclampsia). It can cause a drug-induced lupus-like syndrome, especially in slow acetylators; monitor for arthralgias, rash, and positive ANA. Tachycardia is a common reflex response; often co-administered with a beta-blocker. Avoid in patients with coronary artery disease, high-output heart failure, or mitral valve rheumatic heart disease.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take exactly as prescribed; do not skip doses or double up.,You may experience dizziness or lightheadedness, especially when standing up; rise slowly and avoid sudden position changes.,Report any joint pain, rash, fever, or chest pain to your healthcare provider immediately.,Avoid alcohol, which can worsen side effects like dizziness and low blood pressure.,Do not stop taking this medication abruptly; sudden withdrawal can cause a rapid increase in blood pressure.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DRALZINE vs ALDORIL D30, answered by our medical review team.
DRALZINE is a Antihypertensive that works by Dralzine is a direct-acting arteriolar vasodilator that relaxes vascular smooth muscle, leading to decreased systemic vascular resistance and afterload. The exact molecular mechanism is not fully elucidated but involves inhibition of calcium influx and interference with the contractile process.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DRALZINE and ALDORIL D30 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DRALZINE is: Oral: 50-100 mg twice daily; maximum 200 mg/day.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DRALZINE and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DRALZINE is classified as Category C. First trimester: No evidence of teratogenicity in human studies; however, consider fetal hypotension and impaired uteroplacental perfusion. Second and third trimesters: Risk of fet. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.